{"filing":{"accession_number":"0001193125-26-264392","cik":"0001785279","ticker":"MGX","company_name":"Metagenomi Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"mgx-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm"},"events":[{"id":5942,"run_id":5215,"accession_number":"0001193125-26-264392","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Brian C. Thomas, Ph.D. resigned from his position as a member of the Board of Directors effective June 9, 2026, with the Company confirming the resignation was not due to disagreement.","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5673,"accession_number":"0001193125-26-264392","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Brian C. Thomas, Ph.D. resigned from his position as a member of the Board of Directors effective June 9, 2026. The disclosure explicitly states his resignation and confirms it was not due to disagreement with the Company. This is a straightforward director departure, which is material to investors as board composition affects governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:08.322760+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5943,"run_id":5215,"accession_number":"0001193125-26-264392","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Shareholders voted at the June 9, 2026 annual meeting to elect Juergen Eckhardt and Eric Bjerkholt as Class II Directors and to ratify PricewaterhouseCoopers LLP as the Company's independent auditor, with detailed voting tallies disclosed.","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5674,"accession_number":"0001193125-26-264392","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Metagenomi's June 9, 2026 annual meeting of stockholders. The filing reports final voting tallies for two proposals: (i) election of two Class II Directors (Juergen Eckhardt and Eric Bjerkholt), and (ii) ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote counts (For, Against/Withheld, Abstentions, Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures. Director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:08.322760+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5673,"accession_number":"0001193125-26-264392","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Brian C. Thomas, Ph.D. resigned from his position as a member of the Board of Directors effective June 9, 2026. The disclosure explicitly states his resignation and confirms it was not due to disagreement with the Company. This is a straightforward director departure, which is material to investors as board composition affects governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:08.322760+00:00","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-06-09"},{"id":5674,"accession_number":"0001193125-26-264392","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Metagenomi's June 9, 2026 annual meeting of stockholders. The filing reports final voting tallies for two proposals: (i) election of two Class II Directors (Juergen Eckhardt and Eric Bjerkholt), and (ii) ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote counts (For, Against/Withheld, Abstentions, Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures. Director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:03:08.322760+00:00","company_name":"Metagenomi Therapeutics, Inc.","ticker":"MGX","filing_date":"2026-06-09"}]}